ID   VMM12
AC   CVCL_A734
DR   cancercelllines; CVCL_A734
DR   Cosmic; 890887
DR   GEO; GSM1672073
DR   GEO; GSM1672085
DR   GEO; GSM1672092
DR   GEO; GSM1672110
DR   GEO; GSM1672120
DR   GEO; GSM1672134
DR   Wikidata; Q54993228
RX   PubMed=10752474;
RX   PubMed=14871852;
RX   PubMed=15378283;
RX   PubMed=20856146;
RX   PubMed=26405815;
RX   PubMed=26673621;
CC   HLA typing: A*01,03; B*07,14 (PubMed=10752474).
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=26405815).
CC   Omics: Deep exome analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000029.
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_F863 ! VMM12-EBV
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 19-12-24; Version: 18
//
RX   PubMed=10752474; DOI=10.1007/s002620050015; PMCID=PMC11037162;
RA   Slingluff C.L. Jr., Colella T.A., Thompson L., Graham D.D.,
RA   Skipper J.C.A., Caldwell J., Brinckerhoff L., Kittlesen D.J.,
RA   Deacon D.H., Oei C., Harthun N.L., Huczko E.L., Hunt D.F.,
RA   Darrow T.L., Engelhard V.H.;
RT   "Melanomas with concordant loss of multiple melanocytic
RT   differentiation proteins: immune escape that may be overcome by
RT   targeting unique or undefined antigens.";
RL   Cancer Immunol. Immunother. 48:661-672(2000).
//
RX   PubMed=14871852; DOI=10.1158/0008-5472.CAN-03-2209;
RA   Hogan K.T., Coppola M.A., Gatlin C.L., Thompson L.W., Shabanowitz J.,
RA   Hunt D.F., Engelhard V.H., Ross M.M., Slingluff C.L. Jr.;
RT   "Identification of novel and widely expressed cancer/testis gene
RT   isoforms that elicit spontaneous cytotoxic T-lymphocyte reactivity to
RT   melanoma.";
RL   Cancer Res. 64:1157-1163(2004).
//
RX   PubMed=15378283; DOI=10.1007/s00262-004-0592-y; PMCID=PMC11032761;
RA   Hogan K.T., Sutton J.N., Chu K.U., Caldwell-Busby J.A., Shabanowitz J.,
RA   Hunt D.F., Slingluff C.L. Jr.;
RT   "Use of selected reaction monitoring mass spectrometry for the
RT   detection of specific MHC class I peptide antigens on A3 supertype
RT   family members.";
RL   Cancer Immunol. Immunother. 54:359-371(2005).
//
RX   PubMed=20856146; DOI=10.1097/CMR.0b013e32833fafb4; PMCID=PMC3229868;
RA   Mikesh L.M., Kumar M., Erdag G., Hogan K.T., Molhoek K.R., Mayo M.W.,
RA   Slingluff C.L. Jr.;
RT   "Evaluation of molecular markers of mesenchymal phenotype in
RT   melanoma.";
RL   Melanoma Res. 20:485-495(2010).
//
RX   PubMed=26405815; DOI=10.1371/journal.pone.0138210; PMCID=PMC4583389;
RA   Capaldo B.J., Roller D.G., Axelrod M.J., Koeppel A.F., Petricoin E.F. 3rd,
RA   Slingluff C.L. Jr., Weber M.J., Mackey A.J., Gioeli D., Bekiranov S.;
RT   "Systems analysis of adaptive responses to MAP kinase pathway blockade
RT   in BRAF mutant melanoma.";
RL   PLoS ONE 10:E0138210-E0138210(2015).
//
RX   PubMed=26673621; DOI=10.18632/oncotarget.6548; PMCID=PMC4823068;
RA   Roller D.G., Capaldo B.J., Bekiranov S., Mackey A.J., Conaway M.R.,
RA   Petricoin E.F. 3rd, Gioeli D., Weber M.J.;
RT   "Combinatorial drug screening and molecular profiling reveal diverse
RT   mechanisms of intrinsic and adaptive resistance to BRAF inhibition in
RT   V600E BRAF mutant melanomas.";
RL   Oncotarget 7:2734-2753(2016).
//